What it does
AbbVie is a research-based biopharmaceutical company that develops, manufactures and sells medicines and therapies around the world. It was founded in 2012, is headquartered in North Chicago and is led by Chief Executive Officer Robert A. Michael. Its business operates as a single global segment.
Its medicines span immunology, neuroscience, oncology and eye care. Immunology treatments include Skyrizi, Rinvoq and Humira, which are used for autoimmune and inflammatory conditions. Skyrizi is an injected biologic, while Rinvoq is an oral medicine. The approved uses and available products vary by market.
In neuroscience, AbbVie sells Vraylar for certain psychiatric conditions, Botox Therapeutic for conditions including chronic migraine, and migraine medicines Ubrelvy and Qulipta. Its Parkinson’s treatments include Vyalev and Duodopa. Its cancer medicines include Imbruvica and Venclexta for certain blood cancers and Elahere for certain cancers affecting the ovary and related organs.
The company also sells aesthetic products, including Botox Cosmetic for temporary improvement of facial lines and the Juvederm collection of injectable fillers. Its other products include treatments for hepatitis C and digestive conditions.
AbbVie sells primarily to wholesalers, distributors, government agencies, health care facilities and pharmacies. Physicians and other licensed providers also buy certain products directly, including aesthetic products and devices. Many of its products require a prescription in the United States.
How it makes money
AbbVie earns revenue principally by selling medicines and other health care products. It organizes research, development and supply globally, while commercial teams coordinate marketing, sales and distribution by geography or therapeutic area. The company reports one global business segment rather than separate segments for each product category.
The immunology portfolio includes Skyrizi, Rinvoq and Humira. These medicines treat a range of autoimmune diseases, including forms of arthritis, psoriasis and inflammatory bowel disease. Treatment schedules differ: Skyrizi is injected at intervals after initial doses, while Rinvoq is taken orally once a day. Other products address psychiatric conditions, migraine, Parkinson’s disease and cancer. AbbVie also sells aesthetic injectables, fillers, devices and skin care products.
Some therapies are used for ongoing treatment of chronic conditions. Product revenue can also depend on prescriptions, reimbursement decisions, prices, sales volumes and the introduction of competing products. Outside the United States, AbbVie works with national payer systems in many markets to agree reimbursement terms. Some countries control prices directly or indirectly, and U.S. government programs require specified rebates or discounts.
Certain products are co-marketed or co-promoted. AbbVie also enters licensing and other arrangements that can involve upfront fees, milestone payments, royalties or profit sharing.
For 2025, worldwide net revenue was $61.2 billion; for Q3 2026, total net revenue was $17.4 billion.
For 2026, AbbVie expects total net revenue of approximately $67.8 billion. Its outlook includes Skyrizi revenue of $21.8 billion and Rinvoq revenue of $10.3 billion. The company also expects global neuroscience revenue of $13 billion and oncology revenue of $6.6 billion.
Customers and how it sells
AbbVie sells products worldwide through its own distribution centers and public warehouses. Its direct buyers include wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers. Certain aesthetic products and devices are also sold directly to physicians and other licensed health care providers.
The company directs much of its marketing toward physicians, external experts and other providers who prescribe or recommend its products. Managed care organizations, pharmacy benefit managers, hospitals and government agencies are also important customers. AbbVie markets some products directly to consumers and provides patient support programs connected to its products.
In the United States, independent wholesale distributors handle most pharmaceutical distribution. McKesson, Cardinal Health and Cencora accounted for substantially all of AbbVie’s U.S. pharmaceutical product sales in 2025; no individual wholesaler accounted for greater than 43% of its U.S. gross revenues that year. AbbVie says it has no single customer whose loss would have a material adverse effect on the business.
Outside the United States, AbbVie sells mainly to wholesalers or through distributors and works with national payer systems on reimbursement in many markets. Product availability and approved uses differ by country. For example, Skyrizi and Rinvoq have approvals across North America, the European Union and Japan, while AbbVie’s rights to sell the pancreatic enzyme treatment Creon are limited to the United States.
Suppliers and costs
AbbVie uses a global supply chain for product discovery, development, manufacturing and supply. It also contracts with third parties for work including active pharmaceutical ingredient manufacturing, formulation, filling, finishing, packaging, transportation and distribution.
Some products and services come from a limited number of suppliers or a single source. AbbVie says it maintains alternate supply relationships in most cases and seeks to hold enough inventory to reduce the impact of disruption. It does not consider its manufacturing-related agreements individually material because it says the business is not substantially dependent on any one agreement.
Research and development, manufacturing, selling and administration, regulatory compliance, licensing and acquisitions all require spending. Licensing and partnership arrangements can also carry royalties, milestones or profit-sharing obligations. Biologic therapies generally require substantial investment in production infrastructure.
In Q3 2026, adjusted research and development expense was 13.9% of sales, and adjusted selling, general and administrative expense was 21.2% of sales. In 2025, AbbVie recorded $7.4 billion of intangible asset amortization and $6.5 billion for changes in the fair value of contingent consideration liabilities.
- Revenue$61.2B
- Cost of revenue−$18.2B
- Research and development−$9.1B
- Selling, general and administrative−$14.0B
- Other operating costs−$4.8B
- Operating income$15.1B
Competitive position
AbbVie competes with pharmaceutical and biotechnology companies on treatment options, innovation and price. Its immunology products face other targeted medicines and biosimilars; its oncology medicines compete with targeted drugs, antibody-drug conjugates and cell therapies. Other companies also market products positioned against Botox.
Humira faces direct biosimilar competition globally, as well as pressure from oral products. It was reported on 27 October 2026 that Johnson & Johnson’s oral immunology drug Icotyde could pose a longer-term threat to Skyrizi if its use expands into additional indications.
AbbVie owns or licenses patents and patent applications, including protections related to Skyrizi and Rinvoq. The company expects no U.S. generic entry for Rinvoq tablets before April 2037 under its settlement and license agreements, assuming pediatric exclusivity is granted and subject to standard acceleration provisions. Biologic manufacturing and biosimilar approval also require substantial investment and technical work.
Our reading: Patents and regulatory exclusivity provide product-specific protection, but their strength is limited by expiry, legal challenges and competing treatments, as Humira’s biosimilar competition demonstrates. [item1]
Our reading: Biologics expertise and manufacturing requirements create a meaningful barrier to entry, although they have not prevented follow-on competitors from reaching the market. [item1]
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Johnson & Johnson | Immunology treatments competing with Skyrizi | Medium |
Growth opportunities
AbbVie’s strategy includes expanding sales of medicines already on the market, developing additional uses for them and advancing new products through its pipeline. It also uses acquisitions, licensing and collaborations to obtain compounds and technologies developed elsewhere.
The company’s pipeline included approximately 90 compounds, devices or indications in development, individually or with partners. Approximately 60 programs were in mid- and late-stage development. Its research areas include immunology, neuroscience, oncology, aesthetics and obesity.
AbbVie completed the acquisition of Apogee Therapeutics, adding assets in dermatology and related inflammatory diseases. It also received U.S. approval for an injected-under-the-skin induction option for Skyrizi in Crohn’s disease. AbbVie has started a Phase IIb program combining Skyrizi with other mechanisms in Crohn’s disease and ulcerative colitis.
In neuroscience, the FDA approved Juvmo for Parkinson’s disease. AbbVie expects its Parkinson’s therapies collectively to deliver peak sales of more than $5 billion. In oncology, it has submitted a U.S. application for etentamig in multiple myeloma and anticipates approval in 2027. The company also reported positive Phase III data for Epkinly in previously untreated diffuse large B-cell lymphoma and expects a regulatory submission next year.
AbbVie continues to invest in manufacturing capacity. Its projects include construction of an active pharmaceutical ingredient facility in Illinois and expansion of biologics manufacturing and research capacity in Massachusetts.
- $56.2BFY2021
- $58.1BFY2022
- $54.3BFY2023
- $56.3BFY2024
- $61.2BFY2025
- $2.8BFY2026 guidance
Structural risks
- Loss of exclusivity and competition: Patent or license expiry and competition from generic drugs and biosimilars may reduce revenue and operating earnings. Humira already faces biosimilars globally, while new competing treatments can pressure prices and sales volumes.
- Pricing and reimbursement: Government price controls, mandated rebates and payer restrictions can reduce revenue or limit access. Imbruvica is subject to government-set Medicare prices beginning in 2026, and Vraylar and Linzess were selected for prices beginning in 2027. A court ruling in AbbVie’s favor over Botox’s selection is subject to government appeal.
- Development and regulation: New medicines require clinical testing and regulatory approval. Regulators can also impose post-approval obligations, restrict labels or take enforcement action; studies may lead to limits on marketing or product discontinuation.
- Supply: Some products and services come from limited or single sources. A third party’s failure to perform can disrupt supply, although AbbVie maintains alternatives in most cases and seeks to hold inventory.
- Intellectual property and access: Third-party intellectual property can prevent product sales or affect profitability. Payers’ formulary exclusions, prior authorization and other utilization tools can delay access, raise patient cost-sharing or shift use to competing therapies.
- International operations: Currency changes, trade disruptions, pricing controls and differing local regulations can affect AbbVie’s worldwide business.
Bottom line
Our reading
AbbVie is a global medicines business with aesthetic products and a pipeline built through internal research and external deals. [item1] [item7] Its position rests on marketed therapies and product-specific protections, while biosimilar competition, payer access and government pricing can erode revenue. [item1] Growth depends on expanding existing medicines and bringing pipeline products to market, both of which remain subject to competition and regulatory decisions. [item7] [call_prepared]